Alternative Medicine Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Alternative Medicine Times.

Press releases published on September 2, 2026

Sep. 2, 2026

Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

Indeterminate GlobeNewswire

Sep. 2, 2026

Zevra Therapeutics to Present at Upcoming Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Rezolute to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Indeterminate GlobeNewswire

Sep. 2, 2026

Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026

Indeterminate GlobeNewswire

Sep. 2, 2026

Kaplan Fox Reminds Planet Fitness, Inc. (NYSE: PLNT) Investors with Significant Losses to Seek a Leadership Role Before Deadline on September 14, 2026

Indeterminate GlobeNewswire

Sep. 2, 2026

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Cronos’ brand Spinach® Expands its Best-Selling Lineups of Edibles and Vapes

Indeterminate GlobeNewswire

Sep. 2, 2026

Dyne Therapeutics to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Edible Garden Regains Compliance with Nasdaq Minimum Bid Price Requirement

Indeterminate GlobeNewswire

Sep. 2, 2026

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

Indeterminate GlobeNewswire

Sep. 2, 2026

Kane Biotech Expands Canadian Commercial Reach with Ontario Medical Supply Inc.

Indeterminate GlobeNewswire

Sep. 2, 2026

Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company

Indeterminate GlobeNewswire

Sep. 2, 2026

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

Indeterminate GlobeNewswire

Sep. 2, 2026

Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

Indeterminate GlobeNewswire

Sep. 2, 2026

Cardiff Oncology to Participate in September 2026 Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

Indeterminate GlobeNewswire